^
    Back
    Association details:
    Biomarker:EGFR L861Q + EGFR G719X
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    In Vivo
    Title:

    Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations

    Published date:
    05/02/2020
    Excerpt:
    We report herein a patient with lung adenocarcinoma harboring double uncommon EGFR L861Q and G719X mutations, who is free of disease 32 months after initiation of afatinib therapy. To our best knowledge, this patient has the longest response among other patients with double uncommon mutations.
    DOI:
    10.21873/invivo.11929